Compare TLN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLN | GH |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | 1880 | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | TLN | GH |
|---|---|---|
| Price | $325.61 | $87.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $433.50 | $117.80 |
| AVG Volume (30 Days) | 733.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $58.42 | $33.40 |
| Revenue Next Year | $16.37 | $28.32 |
| P/E Ratio | $83.51 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $162.31 | $36.36 |
| 52 Week High | $451.28 | $120.74 |
| Indicator | TLN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 43.13 |
| Support Level | $307.79 | $82.26 |
| Resistance Level | $397.04 | $90.28 |
| Average True Range (ATR) | 14.64 | 3.61 |
| MACD | 0.71 | 0.45 |
| Stochastic Oscillator | 51.56 | 59.11 |
Talen Energy Corp is an independent power producer and energy infrastructure company based in the United States. It owns and operates several gigawatts of power infrastructure in the United States, including 2.2GW of nuclear power and a dispatchable fossil fleet. The company produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, with its generation fleet principally located in the Mid-Atlantic, Ohio, and Montana. Talen's operating segments are: PJM and Others. The PJM segment, which generates maximum revenue, is engaged in electricity generation, marketing activities, and commodity risk and fuel management within the PJM market and is comprised of Susquehanna and Talen's natural gas and coal generation facilities in PJM.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.